Join BOPA
Back to news articles

Let’s Talk About SACT podcast has been featured in the TOP 40 pharmacology Podcasts worldwide

By BOPA Committee on 3rd May 2025

The BOPA podcast team (Michal Sladkowski, Chiara Creed and Eleanor Meerstadt) are thrilled to share that the Let’s Talk About SACT podcast has been featured in the TOP 40 pharmacology Podcasts worldwide (https://www.millionpodcasts.com/pharmacology-podcasts/)!

A huge thank you to our listeners, guests, and supporters! Your continued support makes this recognition possible.

If you haven’t tuned in yet, now is the perfect time to start. Let’s keep the conversation going- because talking about SACT matters!

#PharmacyPodcast #Let’sTalkAboutSACT

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article